Suppliers and packagers for generic pharmaceutical drug: NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma Ltd	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	207457	ANDA	Aurobindo Pharma Limited	65862-928-36	9 TABLET, FILM COATED in 1 BOTTLE (65862-928-36)	2018-02-15
Sun Pharm	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	202803	ANDA	NorthStar RxLLC	16714-891-01	9 TABLET, FILM COATED in 1 BOTTLE (16714-891-01)	2018-11-27
Sun Pharm	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	202803	ANDA	Sun Pharmaceutical Industries, Inc.	47335-410-22	9 TABLET, FILM COATED in 1 BOTTLE (47335-410-22)	2018-07-20

Naprosyn (Naproxen Sodium) and Sumatriptan Succinate Suppliers: API, Intermediates, and Finished-Dose Sourcing by Region

Last updated: May 26, 2026

Naproxen sodium and sumatriptan succinate have multi-tier supplier ecosystems covering API, key intermediates, and finished-dose outsourcing. Supplier choice is typically governed by (1) regulatory status of the API (DMF/CEP), (2) ability to support branded and generic registrations, (3) breadth of chiral and salt-form control (sumatriptan), and (4) inspection history across FDA/EMA program years.

Which companies supply naproxen sodium API and finished-dose tablets?

Common supplier categories

• API manufacturers (naproxen sodium or naproxen free base with conversion to sodium salt in finished dosage or during API finishing).
• Finished-dose contract manufacturers (CDMOs) for tablets, EC tablets, and co-pack formats under NDA/ANDA arrangements.
• Intermediates suppliers for 2-(6-methoxynaphthalen-2-yl)propanoic acid derivatives and related acylation/aromatization steps.

How to map “suppliers” in practice For commercial and regulatory decisions, “supplier” usually means one of the following:

1. The API holder with the active regulatory filing supporting the U.S. ANDA/DMF or EU CEP.
2. The drug product manufacturer listed on the approved label or ANDA.
3. The developer/CDMO that provides the process and analytical method package used for scale-up.

What patents protect naproxen sodium that affect sourcing?

Naproxen sodium is long off primary patent, so sourcing constraints are less about blocking IP and more about:

• Process patents (salt formation, crystallization control, particle size distribution, polymorph management).
• Formulation patents (enteric coating, dissolution profiles, combination products where naproxen is co-formulated).

For sourcing strategy, this typically translates into requiring suppliers that can demonstrate a process history aligned to the approved ANDA’s specifications and stability data, rather than freedom-to-operate (FTO) against brand patents.

Who supplies sumatriptan succinate API and what does the supply chain look like?

Sumatriptan succinate has tighter technical controls due to:

• Chirality and stereochemical integrity (sumatriptan is the active enantiomer).
• Salt-form consistency for succinate crystallinity and hydration state.
• Purity targets for residual solvents, nitro/alkylation byproducts, and process-related impurities.

Practical supplier segmentation

• API manufacturers producing sumatriptan base then forming the succinate salt under controlled conditions.
• Intermediates suppliers for indole-core elaboration and the sulfonamide/amine substitution steps used to reach the sumatriptan scaffold.
• CDMOs for tablets and film-coated dosage forms with robust dissolution performance.

What patents protect sumatriptan succinate that affect sourcing and generic entry?

Like naproxen, sumatriptan is largely off primary brand exclusivity in most markets. The constraints that affect sourcing are usually:

• Formulation patents on dissolution control, film-coating systems, or specific tablet characteristics.
• Method-of-manufacture patents for the succinate salt formation, impurity control, and crystallization parameter windows.

In supply due diligence, these show up as:

• analytical method reliance on validated impurity panels
• tight raw material acceptance criteria
• controlled polymorph/particle-size specs at lot release

How does supplier selection differ between naproxen sodium and sumatriptan succinate?

Naproxen sodium

• Supplier differentiation often centers on API quality (impurity profile, stability, particle size) and ability to support enteric or modified dissolution tablet specifications.

Sumatriptan succinate

• Supplier differentiation centers on chiral purity, salt integrity, and the ability to consistently meet impurity thresholds that are sensitive to the route of synthesis.

Which regions have the deepest supply base for naproxen sodium and sumatriptan succinate?

Finished-dose and API supply is distributed globally, with the highest density of commercial vendors commonly found across:

• India and China for API and intermediate manufacturing capacity
• EU and U.S. for specific DMF holders, analytical support, and finished-dose manufacturing under established inspections

For sourcing and procurement planning, the key factor is not only vendor density, but also:

• regulatory inspection alignment (FDA and EMA outcomes)
• ability to provide batch documentation and CoAs consistent with ANDA/DMF requirements
• capacity to support ongoing supply and change-control governance

What is the Orange Book status of naproxen sodium and sumatriptan succinate, and does it impact suppliers?

These actives are widely available generically. Supplier impact comes from:

• ongoing ANDA manufacturing and lifecycle maintenance rather than exclusivity blocks.
• product-specific patent listings for particular branded formulations (not typically for the basic API itself).

What generic entry risks exist for naproxen sodium and sumatriptan succinate based on supplier constraints?

Typical generic entry bottlenecks

• inability to match dissolution profile or particle size specs
• variability in salt formation and impurity control for sumatriptan succinate
• change-control events at API or drug product level that can trigger regulatory risk

For procurement, these translate into choosing suppliers with:

• stable process capability
• documented analytics and method transfer readiness
• history of meeting ANDA specification packages

What formulations are protected that could restrict sourcing of naproxen sodium and sumatriptan succinate?

For naproxen sodium, the main formulation restrictions usually relate to:

• enteric-coated performance targets
• combination product formulations (where a different active combination changes the patent landscape)

For sumatriptan succinate, the restrictions usually relate to:

• solid-state form control for tablets
• dissolution and impurity limits tied to succinate salt integrity

What manufacturing/IP barriers typically block new suppliers?

• Method transfer challenges for impurity analytics and controlled crystallization steps
• salt-form policing (especially for sumatriptan succinate)
• regulatory history gaps, including DMF/CEP completeness for the exact grade and process used

Key supplier due diligence checklist for naproxen sodium and sumatriptan succinate

• Regulatory standing: DMF/CEP status for the exact API grade and process
• QC package: validated impurity methods and CoA content aligned to ANDA/market needs
• Solid-state controls:
  • naproxen sodium: particle size distribution and stability for tablet specs
  • sumatriptan succinate: succinate crystallinity, polymorph/hydration control
• Process change governance: ability to support comparability protocols under change-control
• Supply continuity: capacity reservations and batch lead-time predictability
• Inspection readiness: audit support and remediation history where applicable

Key Takeaways

• Naproxen sodium sourcing is mainly differentiated by API quality consistency and the ability to meet formulation dissolution and tablet specification targets.
• Sumatriptan succinate sourcing is more constrained by chirality control, succinate salt integrity, and impurity sensitivity to the synthetic route.
• Supplier selection for both actives is usually governed by regulatory-file alignment (DMF/CEP and ANDA support), plus solid-state/process stability rather than active-pharmaceutical ingredient IP blocking.
• The highest generic and operational risks come from raw material lot variability, method-transfer gaps, and inability to sustain dissolution or impurity compliance across scale.

FAQs

1. How do I evaluate whether an API supplier for naproxen sodium matches an ANDA’s dissolution target?
2. What impurity classes most often drive rejection for sumatriptan succinate API lots?
3. Do enteric-coated naproxen sodium products require different API particle-size specs than immediate-release tablets?
4. What documentation should a sumatriptan succinate supplier provide to support succinate salt form consistency?
5. Which supplier changes are most likely to trigger ANDA comparability reporting for naproxen sodium and sumatriptan succinate?

References

1. FDA. Drug Master Files (DMF) program overview and submission framework. U.S. Food and Drug Administration.
2. EMA. European Medicines Agency guidance on quality of medicines and regulatory filing concepts (CEP/EDMF context). European Medicines Agency.
3. USP. General Chapters and standards relevant to solid dosage form quality attributes (dissolution, performance testing). United States Pharmacopeia.